Cardiff Oncology Inc expected to post a loss of 28 cents a share - Earnings Preview

Cardiff Oncology

27/02/2024 22:04

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
70.7% decrease in revenue to $37.5 thousand from $128 thousand a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Cardiff Oncology Inc is
for a
loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $8.50​, above​ its last closing price of $1.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.28       -0.28      -0.22     Beat    22.8
 Jun. 30 2023  -0.28       -0.26      -0.25     Beat    3.5
 Mar. 31 2023  -0.22       -0.23      -0.25     Missed  -10.6​
 Dec. 31 2022  -0.22       -0.23      -0.20     Beat    14.9
 ​​Sep.        -0.27       -0.26      -0.20     Beat    24.2
 30 2022                                                
 Jun. 30 2022  -0.26       -0.25      -0.24     Beat    4.8​
 Mar. 31 2022  -0.25       -0.23      -0.25     Missed  -8.2
 Dec. 31 2021  -0.17       -0.17      -0.23     Missed  -34
 This summary was machine generated February 27 at 22:04 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)